(S (NP (NP (JJ Adverse) (NN drug) (NNS reactions)) (PRN (-LRB- -LRB-) (NP (NNP ADRs)) (-RRB- -RRB-)) (VP (VBD induced) (PP (IN from) (NP (NP (JJ high-order) (JJ drug-drug) (NNS interactions)) (PRN (-LRB- -LRB-) (NP (NNP DDIs)) (-RRB- -RRB-)) (PP (JJ due) (PP (TO to) (NP (VB polypharmacy)))))))) (VP (VB represent) (NP (DT a) (JJ significant) (JJ public) (NN health) (NN problem))) (. .))
(S (PP (IN In) (NP (DT this) (NN paper))) (, ,) (NP (PRP we)) (VP (ADVP (RB formally)) (VBP formulate) (NP (NP (DT the) (ADJP (JJ to-avoid) (CC and) (JJ safe)) (PRN (-LRB- -LRB-) (PP (IN with) (NP (NP (NN respect)) (PP (TO to) (NP (NNP ADRs))))) (-RRB- -RRB-)) (NN drug) (NN recommendation) (NNS problems)) (SBAR (WHADVP (WRB when)) (S (NP (NN multiple) (NNS drugs)) (VP (VBP have) (VP (VBN been) (VP (VBN taken) (ADVP (RB simultaneously))))))))) (. .))
(S (NP (PRP We)) (VP (VBP develop) (NP (NP (DT a) (JJ joint) (NN model)) (PP (IN with) (NP (NP (DT a) (NN recommendation) (NN component)) (CC and) (NP (DT an) (NNP ADR) (NN label) (NN prediction) (NN component)))) (SBAR (S (VP (TO to) (VP (VB recommend) (PP (IN for) (NP (DT a) (NN prescription))) (NP (NP (DT a) (NN set)) (PP (IN of) (NP (NP (JJ to-avoid) (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (MD will) (VP (VB induce) (NP (NNP ADRs)) (SBAR (IN if) (S (VP (VBN taken) (ADVP (RB together) (PP (IN with) (NP (DT the) (NN prescription)))))))))))))))))))) (. .))
(S (NP (PRP We)) (ADVP (RB also)) (VP (VB develop) (NP (NP (JJ real) (JJ drug-drug) (NN interaction) (NNS datasets)) (CC and) (NP (VBG corresponding) (NN evaluation) (NNS protocols)))) (. .))
(S (NP (NP (PRP$ Our) (JJ experimental) (NNS results)) (PP (IN on) (NP (JJ real) (NNS datasets)))) (VP (VBP demonstrate) (NP (NP (DT the) (JJ strong) (NN performance)) (PP (IN of) (NP (DT the) (JJ joint) (NN model))) (PP (VBN compared) (PP (TO to) (NP (JJ other) (JJ baseline) (NNS methods)))))) (. .))
